# A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer

> **NCT06936488** · NA · ENROLLING_BY_INVITATION · sponsor: **Huai'an First People's Hospital** · enrollment: 35 (estimated)

## Conditions studied

- MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients

## Interventions

- **DRUG:** Ivonescimab,TAS-102

## Key facts

- **NCT ID:** NCT06936488
- **Lead sponsor:** Huai'an First People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-03-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06936488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06936488, "A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06936488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*